Organization
Inflammation, Celgene Co.
1 abstract
Abstract
APREMILAST FOR THE TREATMENT OF BEHÇET’S SYNDROME: A PHASE II RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY Org: Biostatistics Department, Inflammation, Celgene Co., Clinical Research and Medical Affairs, Celgene; Rheumatology – Dept of Medicine, Celgene Co. and UMDNJ, Warren,